Library - Page 13
Registered on ClinicalTrials
The value of atherosclerotic stenizing lesions of the brachiocephalous arteries in the formation of cognitive impairment
Author:
Khasanova D.R., Zhitkova Yu.V., Gasparyan A.A.
Place of publication:
NEUROLOGY. NEUROPSYCHIATRY. Psychosomatics, 2015
The results of the study of the effectiveness and safety of the use of Mexidol in patients with chronic brain ischemia
Author:
E.I. CHUKANOVA, A.S. CHUKANOVA, H.I. MAMAEVA
GBOU VPO “Russian National Research Medical University named after N.I. Pirogov ", Moscow
Oxidative stress and its correction for neurological diseases. Review of literature
Author:
A.I. Fedin
GBOU VPO “Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia
Place of publication:
Neurological practice
Issue No. 2 (5) February 2015
Aleksitimiy in patients with a heart attack of left -handed localization in the late recovery period
Authors:
Antonova N.A. , Kuznetsova E.B., Sholomov I.I.
GBOU VPO "Saratov State Medical University named after V.I. Razumovsky "of the Ministry of Health of Russia, the Department of Nervous Diseases
Place of publication:
Journal of Neurology and Psychiatry, 10, 2015
Neurometabolic therapy as a means of secondary prophylaxis of stroke
Author:
V.V. KOVALCHUK
St. Petersburg GBUZ City Hospital No. 38 named after N.A. Semashko, St. Petersburg
Oxidative stress and its drug correction by Mexidol with traumatic brain injury
Author:
N.V. GOVOROVA
State Budgetary Educational Institution of Higher Professional Education "Omsk State Medical Academy of the Ministry of Health", Omsk, Russia
The effectiveness of the drug "Mexidol" in patients with a combined traumatic brain injury
Authors:
I.B. SAVITSKAYA, V.V. NIKONOV, A.V. CHERNOV, A.Yu. PAVLENKO, A.V. BELETSKY
Kharkov Medical Academy of Postgraduate Education, Kharkov City Clinical Hospital of Emergency and Emergency Medical Assistance
Clinical experience in the use of Mexidol to correct astheno-vegetative disorders in patients who have suffered a mild traumatic brain injury
Author:
M.E. SERGIENKO
Road Clinical Hospital, Chelyabinsk
Features of the influence of Mexidol on the functional state of the central nervous system in patients who have suffered a stroke
Authors:
V.V. Kuznetsov, F.V. Yurchenko
Institute of Gerontology of AMNs of Ukraine, Kyiv
Clinical assessment of the drug Mexol in the treatment of severe traumatic brain injury at the stages of medical care
Author:
V.L. RADUSHKEVICH
Voronezh State Medical Academy. N. N. Burdenko, Voronezh
Experience with the use of Mexidol in the treatment of concussion and in the late recovery period after severe traumatic brain injury in outpatient settings
Author:
A.V. IGNATOVA
Municipal Health Institution City Polyclinic No. 26, Novosibirsk
Randomized dual-blind, placebo-controlled study of the effectiveness and safety of Mexidol in the complex therapy of ischemic stroke in the acute period
Author:
V. I. SKBORTSOVA, L. V. STAKHOVSKAYA, Y. R. NARCISSOV, M. K. BODYKHOV, I. V. KICHUK, Y. V. GUDKOVA, T. A. SOLDATENKOVA, T. T. KONDRASHOVA, E. V. KALININA, M. A. NOVICHKOVA, O. B. KERBIKOV
Department of Fundamental and Clinical Neurology of the Russian State Medical University, Research Institute of Cytochemistry and Molecular Pharmacology, Moscow
Mexidol in the prevention of intracranial hypertension syndrome with the consequences of closed traumatic brain injury
Authors:
B.M. DORONIN, A.YU. LETYAGIN, O.B. TYSHKEVICH, V.B. DORONIN
Novosibirsk State Medical University, Novosibirsk, 2006
The possibility of using Mexidol in neuropediatrics
Authors:
N.N. ZAVADENKO, N.YU. SUVORINOVA, A.N. ZAVADENKO
FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia
The results of a multicenter dual blind randomized placebo-controlled clinical study on the assessment of the effectiveness and safety of the drug Mexidol in the treatment of attention deficit syndrome in children (mega)
Registered on ClinicalTrials
N.N. ZAVADENKO1, N.Yu. SUVORINOVA1, T.T. BATYSHEVA2, O.V. BYKOVA2, A.N. PLATONOVA2, D.D. GAYNETDINOVA3, E.V. LEVITINA4, V.V. MASHIN5, I.N. VAKULA6, N.E. MAKSIMOVA7
1Pirogov Russian National Research Medical University, Moscow, Russia;
2Scientific and Practical Center for Child Psychoneurology, Moscow Department of Health, Moscow, Russia;
3Kazan State Medical University, Kazan, Russia;
4Tyumen State Medical University, Tyumen, Russia;
5Ulyanovsk State University, Ulyanovsk, Russia;
6Center for Professional Therapy, Krasnodar, Russia.
7FSBEI in the Tver State Medical University, Tver, Russia
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2022, Vol. 122, No. 4
Experience in the use of Mexidol® in children and adolescents with mental disorders
Authors:
Yu.Sh. Vasyanina
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com